Pertuzumab Biosimilar BLA for HER2+ Breast Cancer Accepted by FDA
After a phase 3 study showed a promising pCR rate with HLX11, the pertuzumab biosimilar’s BLA has been accepted for review by the FDA.
Related Articles
2024 Blood Journal Contest
9th Annual Blood Cover Art Contest is now open. In recognition of authors who published in Blood and images used in advancement of science, we…
Patient-Centered Cancer Care Improved Through Nutrition Support – Oncology Nurse Advisor
This report on nutrition among patients with cancer highlights current and potential roles for oncology nurses in incorporating nutrition care into cancer care.
Neuropathy in Amyloidosis – Amyloidosis Research Consortium
This booklet discusses the various impacts that amyloidosis may have on a patient’s nerves and potential management techniques.
Personalized Cancer Vaccine May Trigger Anti-Tumor Response in RCC
In a phase 1 trial, all 9 patients with renal cell carcinoma treated with a neoantigen-targeting personalized cancer vaccine showed no recurrence at data cutoff.
Advanced Breast Cancer at Diagnosis Linked to 10% Higher CVD Risk
Kevin T. Nead, MD, MPhil, details findings on the association between prevalent CVD and breast cancer and next steps for investigating the connection.
Conditional Activation of c-MYC in Distinct Catecholaminergic Cells Drives Development of Neuroblastoma or Somatostatinoma
The development of c-MYC–driven genetically engineered neuroblastoma and somatostatinoma mouse models provides useful tools for understanding the tumor cell origin and investigating treatment strategies.
Asciminib plus dasatinib and prednisone for Philadelphia chromosome–positive acute leukemia
Key PointsDasatinib, asciminib, and prednisone can be safely combined for the dual targeting of BCR::ABL1 in Ph+ acute leukemia.Dasatinib and asciminib com
The Benefits of Palbociclib in HR+, HER2+ Metastatic Breast … : Oncology Times
An abstract is unavailable.
Five-Year Data Confirm Benefit of Nivolumab in Upper GI Cancer
David B. Zhen, MD, discusses the results of the phase 3 CheckMate 649 trial in patients with advanced gastric cancer, gastroesophageal junction cancer, and esophageal…
Chemotherapy shortages did not increase short-term mortality for people with advanced cancer
The shortage of generic chemotherapy drugs cisplatin and carboplatin that began in early 2023 did not increase short-term mortality rates among people with advanced cancer,…
